Sanofi Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Sanofi, a foreign private issuer, for the month of December 2017. The filing serves to incorporate by reference two press releases issued in December 2017 regarding specific regulatory developments in the company's pipeline.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory update and does not contain financial statements or performance metrics.
Material Changes and Regulatory Updates
- Patisiran Submission: On December 18, 2017, Sanofi and Alnylam submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for patisiran, intended for the treatment of hereditary ATTR amyloidosis.
- Fitusiran Clinical Hold Lifted: On December 15, 2017, the U.S. Food and Drug Administration (FDA) lifted the clinical hold on fitusiran, allowing clinical trials to proceed.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on overall outlook, or a discussion of general risks and contingencies. The content is limited to the specific regulatory milestones noted above.
Investor Verification Checklist
- Verify the status of the EMA review for patisiran following the December 18 submission.
- Confirm the timeline for the resumption of clinical trials for fitusiran following the FDA's lifting of the clinical hold.
- Review the full text of the attached press releases (Exhibits 99.1 and 99.2) for detailed clinical data or partnership terms not summarized in this filing.